Skip to content

GRAIL, Inc. GRAL Preferred Stock, Shares Authorized

Preferred Stock, Shares Authorized at other companies

Abbott logo
AbbottABT
Guardant Health logo
Guardant HealthGH
Tempus AI, Inc. logo
Tempus AI, Inc.TEM
GeneDx Holdings logo
GeneDx HoldingsWGS
Celcuity logo
CelcuityCELC
Precigen logo
PrecigenPGEN

Other financials

Income statement

See full
Revenue$40.8M+28.1%
Operating income-$135.8M+11.6%
Net income-$93.2M+12.3%
EPS (diluted)-$2.29+26.1%

Balance sheet

See full
Cash & equivalents$76.3M-44.4%
Total debt$51.0M-20.7%
Total equity$2.5B+3.6%
Total assets$2.8B-1.5%

Cash flow

See full
Operating cash flow-$87.0M+8.4%
CapEx$503.0K+711%
Free cash flow-$87.5M+8.0%

Valuation

See full
Market cap$2.62B+145%
Enterprise value$2.6B+164%
P/S16.8×+8.6×

Profitability

See full
Operating margin-348.7%-153pp
Net margin-253.2%-115pp
FCF margin-187.2%-60.4pp

Returns & leverage

See full
Return on equity-16.1%
Debt / equity0.0×
Current ratio11.7×+2.0×

Where this comes from

Reported directly by GRAIL, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockSharesAuthorized.

The official record: GRAIL, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about GRAIL, Inc.'s preferred stock, shares authorized.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is GRAIL, Inc.'s preferred stock, shares authorized?
GRAIL, Inc. (GRAL) reported preferred stock, shares authorized of $50M in Q1 2026.
How has GRAIL, Inc.'s preferred stock, shares authorized changed year-over-year?
GRAIL, Inc.'s preferred stock, shares authorized decreased by 0.0% year-over-year, from $50M to $50M.
What is the long-term trend for GRAIL, Inc.'s preferred stock, shares authorized?
Over 2 years (2023 to 2025), GRAIL, Inc.'s preferred stock, shares authorized has grown at a 0.0% compound annual growth rate (CAGR), from $50M to $50M.